



# Cognitive Testing for the Workplace

Never Stand Still

Medicine

Psychiatry

**Professor Henry Brodaty**  
**Centre for Healthy Brain Ageing (CHeBA)**  
**Dementia Centre for Research Collaboration**  
**University of New South Wales**  
**[h.brodaty@unsw.edu.au](mailto:h.brodaty@unsw.edu.au)**



# Why do cognitive screening?

- Routine eg after certain age
  - eg pilots, train drivers, doctors under new APHRA guide judges?, politicians?

# Importance of collateral history

- Pivotal in clinical practice
- More difficult in workplace
- Reports from work

# Should we diagnose before symptoms appear?

- By screening people at risk?
- By measuring biomarkers?

# Role of cognitive screening

- **50-80% of dementia are undiagnosed**
- **At least 50% of mild & moderate dementia cases are missed by physicians, improves for moderately advanced dementia**
- **Target of testing should be those with risk factors (age, FH, genotype) & when there are symptoms**
  - **Not just those who present to medical centres for other reasons.. Not universal screening**

Ashford et al. *Alzheimer's & Dementia*. 2006; 2:76-85



# Screening: the case for

- Reversible cause
- Start anti-AD Rx earlier
- Relief to patient
- Relief to family
- Legal: enduring POA/ guardianship
- Better Mx comorbid  $\Delta$
- Life decisions
- Driving
- Work
- >attention to life-style



# Screening: the case against

- No Rxx proven
- Lifestyle/ legal should be for all
- False positives
- False negatives
- Cost
- Alarm pt/ family
- No RCT that earlier Dx improves outcome

# Major objectives of a good screening program

1. Detection of disease at a stage when treatment can be *more effective* than it would be after pt develops Sg & Sx... ??
2. Identification of risk factors to prevent or lessen the disease by modifying the risk factors ... *Possibly but do not need to screen*



# Criteria for screening test

1. Disease should constitute a significant public health problem ... ✓✓✓
2. Have readily available treatment with potential for cure that increases with early detection .. ✗
3. Test must be capable of detecting a high proportion of disease in preclinical state ... ?✓

# Criteria for screening test

4. Be safe to administer ... ✓
5. Be reasonable in cost ... ✓
6. Lead to demonstrated better health outcomes ?
7. Be widely available, as must the interventions that follow a positive result ... ?✓

# Good screening tools have...

- **High sensitivity**  
**=  $a / a + c$**
- **High specificity**  
**=  $d / b + d$**
- **PPV =  $a / a + b$**
- **NPV =  $d / c + d$**

	Disease present	Disease absent	
Test positive	a = true positive	b = false positive	Total test +ve
Test negative	c = false negative	d = true negative	Total test -ve
	Total disease	Total non-disease	Total populat <sup>n</sup>

# Effect of prevalence


- **As prevalence rises**
  - **PPV increases**
  - **PNV decreases**
- **High prevalence populations**
  - **Age:  $\geq 75$  10%;  $\geq 80 = 20\%+$ ;  $\geq 90 = 30\%+$**
  - **Age + hospital:  $\geq 70 \geq 40\%^1$**
  - **RACF: 50 – 70%**
  - **Family history, ApoE4 etc**

Sampson EL, Brit J Psychiatry, 2009: 191:61-66




# At what age should screening commence?

Age 65+



Age 85+



Test Accuracy

Se = Sensitivity  
Sp = Specificity



# If screen positive....

- This is not diagnosis of dementia
- False positives - poor cognitive performance 2° to sensory impairment, education, language, developmental disability
- Positive screen  $\neq$  dementia, eg acute illness, depression, medication
- Desirable to have test with high sensitivity *followed by second stage assessment*



# Screening instruments

## *Brief*

- MMSE
- sMMSE
- MOCA
- AMTS
- GPCOG
- Memory Impairment Scale
- Minicog
- PAS-CDS
- RUDAS
- KICA

## *Longer*

- ACE-R
- 3MS
- Cued recall
- ADAS-COG

DOMS website

<http://dementiakt.com.au/doms/>





# Welcome to DOMS

## DOMAINS

- Cognition
- Staging
- Function
- Behaviour
- Delirium
- Quality of life

## ABOUT

## DOWNLOADS

## FAQ





## COGNITION SCALES

Dementia Outcomes Measurement Suite  
<http://www.dementia-assessment.com.au>

	Psychometrics*	User-friendliness <sup>#</sup>	Time	Cost	Specific strengths
--	----------------	--------------------------------	------	------	--------------------

### Very brief screening

<u>GPCOG</u>	●	●	●	●	Screen plus optional informant measure
<u>MiniCog</u>	●	●	●	●	Very brief
<u>AMTS</u>	●	●	●	●	No materials required; long history of use;
<u>FAB</u>	●	●	●	●	Executive dysfunction

### Screening

<u>MoCA</u>	●	●	●	●	Mild cognitive impairment
<u>3MS</u>	●	●	●	●	Extension of MMSE with excellent psychometrics
<u>S-MMSE</u>	●	●	●	●	MMSE with standardised administration
<u>MMSE</u>	●	●	●	●	Very widespread use
<u>RUDAS</u>	●	●	●	●	Low literacy; easily translated into different languages

### Comprehensive

<u>ACE-III</u>	●	●	●	●	Differential diagnosis
<u>ADAS-Cog</u>	●	●	●	●	Measuring change in drug

# How to do cognitive testing

- **Seek permission, explain purpose**
- **Seating, chairs, lighting, no distractions**
- **Correct vision, hearing if possible**
- **Interpreter if needed**
- **Appropriate test**

# Cognitive Ax without testing

## *At interview*

- **Appearance, non-verbal**
- **History**
  - **dates, specificity**
- **Speech**
- **Vocabulary**
- **Anticipation**
- **Humour**



# Limitations of testing

## *Person*

- Variable performance
- Motivation
- Psychological
- Physical limitations
- Medications
- Comorbidity

## *Tester*

## *Test*

- Education bias
- Ceiling effects
- Floor effects
- Domains not tested

## *Context*

- Practice effect
- Language



# Challenging cases

- **Intellectual disability**
- **Mental illness eg Sz, depression**
- **Physical illness**
- **Malingering**
- **Is it delirium? Dementia? Delirium + dementia?**
- **MCI vs dementia, especially when no informant**
- **Near centenarians and centenarians**



# Driving

- **Moderately severe and severe dementia – stop driving**
- **Early- moderate ??**
- **Poor correlation with cognitive testing**
- **Driving assessment required**





# Understanding Neuropsychological Assessment

Never Stand Still

Dr Nicole Kochan



# Outline of neuropsychology

- **Overview of assessment process**
- **Role of NP Ax in dementia & MCI**
- **What do we test? Cognitive domains & processes**
- **Limitations of NP Ax**




Dr Nicole Kochan





# What is neuropsychological assessment?



# Role of neuropsychological assessment in MCI & dementia



- **Detect cognitive impairment/ decline**
  - sensitive to subtle impairment in mild neurocognitive disorders – MCI
- **Differential diagnosis**
- **Monitor cognitive change**
- **Prognosis**
- **Predicting functional ability**

# Cognitive domains

- **Premorbid ability**
- **Attention and working memory**
- **Processing speed**
- **Learning and Memory**
- **Language**
- **Visuo-spatial ability**
- **Executive function**
- **Mood**



# Estimating premorbid ability

## National Adult Reading Test (NART)

psalm

courteous

drachm

gauche

demesne

## Wechsler Test of Adult Reading (WTAR)

gnat

aesthetic

treatise

hyperbole

insouciant



# Cognitive domains

- Premorbid ability
- **Attention and working memory**
- Processing speed
- Learning and Memory
- Language
- Visuo-spatial ability
- Executive function
- Mood
- Social awareness



# Tests of Attention and Working Memory

- **Digits forward and backward**
- **‘Mental control’/series**
- **e.g. months backward, serial 7s**

# Cognitive domains

- Premorbid ability
- Attention and working memory
- **Processing speed**
- Learning and Memory
- Language
- Visuo-spatial ability
- Executive function
- Mood

# Digit Symbol Coding

## Coding

1	2	3	4	5	6	7	8	9
└	⌋	∧	—		┌	⊂	└	└

Demo			Sample														
6	8	3	9	5	4	1	7	2	1	4	8	2	7	6	9	3	5
8	3	1	9	2	5	6	4	3	7	2	9	8	1	4	7	6	5
9	1	2	4	7	2	5	6	9	5	8	6	4	3	1	7	8	3
1	3	9	6	3	9	7	5	1	4	2	8	7	2	8	5	6	4
7	6	4	1	3	2	8	1	7	9	2	5	3	4	8	6	5	9
8	1	9	5	1	4	2	6	9	8	7	3	5	6	4	7	2	3
3	6	8	9	1	8	4	7	5	2	9	6	7	1	5	2	3	4
6	4	1	9	5	7	3	6	8	3	2	7	5	8	4	2	9	1





# Cognitive domains

- Premorbid ability
- Attention and working memory
- Processing speed
- **Learning and Memory**
- Language
- Visuo-spatial ability
- Executive function
- Mood

# Verbal Memory Tests

- Story recall: “**Logical Memory**”
  - 25 elements; Immediate & Delayed recall
- Word list learning:

## Rey Auditory Verbal Learning Test (RAVLT)


- List A: 15 words (5 repeated presentations)
- List B: 15 words (interference list)
- Immediate recall List A
- Delayed recall List A (20-30’ later)
- Recognition words

drum  
curtain  
bell  
coffee  
school  
parent  
moon  
garden  
hat  
farmer  
nose  
turkey  
colour  
house  
river





# Visual Memory Tests

- **Simple Designs: Visual Reproduction**
- less complex



# Visual Memory Tests

- **Simple Designs: Visual Reproduction**
- more complex





# Cognitive domains

- Premorbid ability
- Attention and working memory
- Processing speed
- Learning and Memory
- **Language**
- Visuo-spatial ability
- Executive function
- Mood

# Language Tests

- Confrontation Naming: **Boston Naming Test**



# Language Tests

- Fluency measures: **Semantic or category fluency**
- 
- **Animals, Fruits, Vegetables, Boy's names, Countries**

# Language Tests

- **Fluency measures:**
- **Controlled Oral Word Association Test/  
Letter fluency (FAS)**
- **“Test Experience”**







# Verbal fluency additional measures

- **Rule breaks and repetitions provide information about attentional control, self-monitoring and perseverative thinking**


# Cognitive domains

- Premorbid ability
- Attention and working memory
- Processing speed
- Learning and Memory
- Language
- **Visuo-spatial ability**
- Executive function
- Mood






# Rey Complex Figure




Case MF  
AD, good  
planning,  
construction




## Case AL

AD, mild  
problems w  
planning



## Case JS

vascular dementia, severe  
constructional difficulties





Rey Figure Copy.



Case RB

DLB, severe  
spatial &  
construction  
difficulties

# Cognitive domains

- Premorbid ability
- Attention and working memory
- Processing speed
- Learning and Memory
- Language
- Visuo-spatial ability
- **Executive function** -reasoning, problem-solving, concept formation, mental flexibility, planning
- Mood


- **Verbal abstract thinking – ‘Similarities’**
- In what way are an orange and a banana alike?
- In what way are work and play alike?
- In what way are praise and punishment alike?

# Scoring similarities – work & play


- **2 points:**
- **basic human activities, activities valued by society, daily activities we do**
- **1 point:**
- **ways to spend your time, part of life, can get enjoyment from them**
- **0 point:**
- **Keep you out of trouble, play is fun but work is serious, they're opposites**



# Trail Making Test A



## Trail Making Test B



# Cognitive domains

- Premorbid ability
- Attention and working memory
- Processing speed
- Learning and Memory
- Language
- Visuo-spatial ability
- Executive function
- **Mood**

# How normal distinguished from abnormal?

## Normative data

- Test data collected on a group of healthy individuals
- Comparing performance of an individual to a normative sample provides info about their relative standing in the group
- Validity of npsych results depends on match between individual being tested & normative sample, in regards to sociodemographic characteristics






# Limitations of Neuropsychological Ax

- Problem of base rates
- Frequency of low test scores in the normative sample on a particular test battery
- 1 or 2 impairments on a large test battery may lead to misdiagnosis
- neuropsych scores cannot be interpreted in isolation


# Biomarkers

- **CT & MRI Scans**
- **ApoE  $\epsilon$ 4**
- **CSF -  $\downarrow$ A $\beta$ ,  $\uparrow$ tau and P-tau**
- **PET Amyloid imaging**
- **PET Tau imaging**
- **Dopamine Transporter Imaging SPECT  
(ligand not available in Australia)**

# Hippocampal atrophy in Alzheimer's




# PET amyloid imaging: normal vs AD




- 35% persons 60+ amyloid+
- Amyloid+ → ↑ risk clinical progression
- Will all amyloid+ develop AD?
- When??

Hotter colours = more amyloid


# Tau imaging



# A $\beta$ & tau imaging



# DAT Scan for LBD



# Conclusions

- **Assessing cognition is more than an MMSE**
- **History, history, history**
- **Physical and mental state**
- **Consider medications, context**
- **Brief cognitive testing is just a first step**
- **Neuropsychological testing is long procedure, stressful and expensive**
- **Testing cognition can have work, insurance and personal consequences**



# Thank you

CHeBA [www.cheba.unsw.edu.au](http://www.cheba.unsw.edu.au)

**Dementia Outcomes Measurement Suite**

<http://dementiakt.com.au/doms/>

**DCRC** [www.dementiaresearch.org.au](http://www.dementiaresearch.org.au)